Previous Close | 4.0200 |
Open | 4.0200 |
Bid | 4.1400 x 0 |
Ask | 4.2600 x 0 |
Day's Range | 4.0200 - 4.0600 |
52 Week Range | 4.0000 - 11.2000 |
Volume | |
Avg. Volume | 0 |
Market Cap | 150.904M |
Beta (5Y Monthly) | 0.05 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.3200 |
Earnings Date | May 08, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.67 |
FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and
scPharmaceuticals Inc. ( NASDAQ:SCPH ) shareholders might be concerned after seeing the share price drop 23% in the...
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call Transcript March 13, 2024 scPharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.35, expectations were $-0.48. SCPH isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to scPharmaceuticals Fourth Quarter and […]